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Human noroviruses were difﬁcult to identify before the
molecular era in diagnostics, but they now constitute the
leading cause of acute gastroenteritis in all age groups. These
environmentally stable and highly contagious viruses spread
through water or food, or directly from person to person.
Outbreaks of gastroenteritis can occur in all regions of the
world and throughout the year, but most norovirus gastro-
enteritis cases occur during the winter period; hence the
originally proposed name of ‘winter vomiting disease’.
The four reviews of this special issue provide updates on
the current knowledge about the evolution of noroviruses, the
burden of noroviruses in immunocompetent or immunocom-
promised people, and the control of norovirus disease. The
study of White [1] shows the mechanisms of the evolution of
noroviruses, especially genogroup II genotype 4 (GII.4), the
most prevalent norovirus. This genotype undergoes antigenic
drift on the external domain of its capsid protein (P2 domain),
allowing it to escape herd immunity. This immune selection
drives antigenic changes that contribute to the emergence of
novel GII.4 variants. This mechanism has been observed in the
last two decades in the GII.4 norovirus that was responsible
for the last six major gastroenteritis pandemics. Besides this
antigen drift mechanism, RNA recombination is the other
major driving force that contributes to the evolution of
contemporary norviruses. RNA recombination is promoted by
the presence of a breakpoint at the open reading frame (ORF)
1–ORF2 overlap.
The studies by Belliot et al. [2] and Green [3] show the
clinical aspects of the disease and the burden of norovirus
gastroenteritis. Diarrhoea and vomiting are the predominant
symptoms; others may include abdominal cramps, fever,
headache, chills, and myalgia. Fortunately, the illness is usually
mild, and lasts for <3 days. Nevertheless, some population
groups are at higher risk or are more vulnerable than others.
Young children have the highest incidence of norovirus
gastroenteritis, which causes up to 200 000 deaths of children
aged <5 years in developing countries. Elderly people living in
nursing homes constitute the other largest population group
with a particularly high risk of winter outbreaks of norovirus
gastroenteritis. Dissemination of human noroviruses in these
two populations is favoured by the extreme genetic hetero-
geneity within these viruses and the emergence of new
variants. One other population, the immunocompromised, is
also more vulnerable. In such individuals, norovirus can cause
chronic infection, which can become debilitating and
life-threatening.
Besides their clinical burden, norovirus infections result in
signiﬁcant costs for healthcare and the food industry. Without
effective treatment or vaccination, infection control is based
on the strict application of hygiene programmes, ranging from
cleaning to isolation and cohorting. The study of Barclay et al.
[4] reviews infection control guidelines for norovirus, and
addresses future strategies regarding these.
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